ER-60 (PDIA3) is highly expressed in a newly established serous ovarian cancer cell line, YDOV-139

Doobyung Chay, Hanbyoul Cho, Beom Jin Lim, Eun Suk Kang, Yoon Jin Oh, Sun Mi Choi, Bo Wook Kim, YoungTae Kim, Jae-Hoon Kim

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Characterization of a newly established serous ovarian cancer cell line, YDOV-139 was performed and ER-60 (PDIA3), which was highly expressed in YDOV-139, was evaluated as novel biomarker for ovarian cancer. The YDOV-139 cell line was established using ascites samples from a 67-year-old Korean woman with recurrent ovarian cancer, and was characterized with respect to various biological and genetic features. Gene expression profiles were analyzed using cDNA microarrays, and proteomic evaluation was performed by two-dimensional gel electrophoresis (2-DE) and matrix-assisted laser desorption ionization-time of flight peptide mass fingerprinting (MALDI-TOF/PMF). Four candidate markers that were strongly up-regulated in YDOV-139 were validated by real-time polymerase chain reaction (PCR) and immunohistochemistry (IHC). The epithelial-like characteristics of YDOV-139 were evident from morphologic studies, and the average population doubling time was 120 h. When transplanted into nude mice, YDOV-139 cells successfully induced tumor masses in all three animals. Chemosensitivity tests showed that gemcitabine had the highest chemosensitivity index against YDOV-139 cells. HLA typing revealed A*24/A*31, B*07/B*35, Cw03*(09)/w*07, and DRB1*01/ DRB1*15 alleles. Compared with human ovarian surface epithelial (HOSE) cells, 2,520 genes and 23 protein spots were differentially expressed in YDOV-139. Validation by real-time PCR showed that mRNA expression of LCN2, MDK, SLCO4A1, and ER-60 (PDIA3) were strongly elevated in ovarian cancers. In IHC analysis, ER-60 (PDIA3) was significantly overexpressed in both borderline tumors and invasive ovarian cancers (P<0.001). The molecular characteristics of YDOV-139 may have implications for future ovarian cancer research and ER-60 (PDIA3) should be investigated further as a potential biomarker of ovarian cancer.

Original languageEnglish
Pages (from-to)399-412
Number of pages14
JournalInternational Journal of Oncology
Volume37
Issue number2
DOIs
Publication statusPublished - 2010 Aug 1

Fingerprint

Ovarian Neoplasms
Cell Line
gemcitabine
Real-Time Polymerase Chain Reaction
Biomarkers
Immunohistochemistry
Histocompatibility Testing
Peptide Mapping
Electrophoresis, Gel, Two-Dimensional
Oligonucleotide Array Sequence Analysis
Transcriptome
Ascites
Nude Mice
Proteomics
Neoplasms
Lasers
Epithelial Cells
Alleles
Messenger RNA
Research

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Chay, Doobyung ; Cho, Hanbyoul ; Lim, Beom Jin ; Kang, Eun Suk ; Oh, Yoon Jin ; Choi, Sun Mi ; Kim, Bo Wook ; Kim, YoungTae ; Kim, Jae-Hoon. / ER-60 (PDIA3) is highly expressed in a newly established serous ovarian cancer cell line, YDOV-139. In: International Journal of Oncology. 2010 ; Vol. 37, No. 2. pp. 399-412.
@article{5bdbd8bd07504d98a2d7c186d6362669,
title = "ER-60 (PDIA3) is highly expressed in a newly established serous ovarian cancer cell line, YDOV-139",
abstract = "Characterization of a newly established serous ovarian cancer cell line, YDOV-139 was performed and ER-60 (PDIA3), which was highly expressed in YDOV-139, was evaluated as novel biomarker for ovarian cancer. The YDOV-139 cell line was established using ascites samples from a 67-year-old Korean woman with recurrent ovarian cancer, and was characterized with respect to various biological and genetic features. Gene expression profiles were analyzed using cDNA microarrays, and proteomic evaluation was performed by two-dimensional gel electrophoresis (2-DE) and matrix-assisted laser desorption ionization-time of flight peptide mass fingerprinting (MALDI-TOF/PMF). Four candidate markers that were strongly up-regulated in YDOV-139 were validated by real-time polymerase chain reaction (PCR) and immunohistochemistry (IHC). The epithelial-like characteristics of YDOV-139 were evident from morphologic studies, and the average population doubling time was 120 h. When transplanted into nude mice, YDOV-139 cells successfully induced tumor masses in all three animals. Chemosensitivity tests showed that gemcitabine had the highest chemosensitivity index against YDOV-139 cells. HLA typing revealed A*24/A*31, B*07/B*35, Cw03*(09)/w*07, and DRB1*01/ DRB1*15 alleles. Compared with human ovarian surface epithelial (HOSE) cells, 2,520 genes and 23 protein spots were differentially expressed in YDOV-139. Validation by real-time PCR showed that mRNA expression of LCN2, MDK, SLCO4A1, and ER-60 (PDIA3) were strongly elevated in ovarian cancers. In IHC analysis, ER-60 (PDIA3) was significantly overexpressed in both borderline tumors and invasive ovarian cancers (P<0.001). The molecular characteristics of YDOV-139 may have implications for future ovarian cancer research and ER-60 (PDIA3) should be investigated further as a potential biomarker of ovarian cancer.",
author = "Doobyung Chay and Hanbyoul Cho and Lim, {Beom Jin} and Kang, {Eun Suk} and Oh, {Yoon Jin} and Choi, {Sun Mi} and Kim, {Bo Wook} and YoungTae Kim and Jae-Hoon Kim",
year = "2010",
month = "8",
day = "1",
doi = "10.3892/ijo-0000688",
language = "English",
volume = "37",
pages = "399--412",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "2",

}

ER-60 (PDIA3) is highly expressed in a newly established serous ovarian cancer cell line, YDOV-139. / Chay, Doobyung; Cho, Hanbyoul; Lim, Beom Jin; Kang, Eun Suk; Oh, Yoon Jin; Choi, Sun Mi; Kim, Bo Wook; Kim, YoungTae; Kim, Jae-Hoon.

In: International Journal of Oncology, Vol. 37, No. 2, 01.08.2010, p. 399-412.

Research output: Contribution to journalArticle

TY - JOUR

T1 - ER-60 (PDIA3) is highly expressed in a newly established serous ovarian cancer cell line, YDOV-139

AU - Chay, Doobyung

AU - Cho, Hanbyoul

AU - Lim, Beom Jin

AU - Kang, Eun Suk

AU - Oh, Yoon Jin

AU - Choi, Sun Mi

AU - Kim, Bo Wook

AU - Kim, YoungTae

AU - Kim, Jae-Hoon

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Characterization of a newly established serous ovarian cancer cell line, YDOV-139 was performed and ER-60 (PDIA3), which was highly expressed in YDOV-139, was evaluated as novel biomarker for ovarian cancer. The YDOV-139 cell line was established using ascites samples from a 67-year-old Korean woman with recurrent ovarian cancer, and was characterized with respect to various biological and genetic features. Gene expression profiles were analyzed using cDNA microarrays, and proteomic evaluation was performed by two-dimensional gel electrophoresis (2-DE) and matrix-assisted laser desorption ionization-time of flight peptide mass fingerprinting (MALDI-TOF/PMF). Four candidate markers that were strongly up-regulated in YDOV-139 were validated by real-time polymerase chain reaction (PCR) and immunohistochemistry (IHC). The epithelial-like characteristics of YDOV-139 were evident from morphologic studies, and the average population doubling time was 120 h. When transplanted into nude mice, YDOV-139 cells successfully induced tumor masses in all three animals. Chemosensitivity tests showed that gemcitabine had the highest chemosensitivity index against YDOV-139 cells. HLA typing revealed A*24/A*31, B*07/B*35, Cw03*(09)/w*07, and DRB1*01/ DRB1*15 alleles. Compared with human ovarian surface epithelial (HOSE) cells, 2,520 genes and 23 protein spots were differentially expressed in YDOV-139. Validation by real-time PCR showed that mRNA expression of LCN2, MDK, SLCO4A1, and ER-60 (PDIA3) were strongly elevated in ovarian cancers. In IHC analysis, ER-60 (PDIA3) was significantly overexpressed in both borderline tumors and invasive ovarian cancers (P<0.001). The molecular characteristics of YDOV-139 may have implications for future ovarian cancer research and ER-60 (PDIA3) should be investigated further as a potential biomarker of ovarian cancer.

AB - Characterization of a newly established serous ovarian cancer cell line, YDOV-139 was performed and ER-60 (PDIA3), which was highly expressed in YDOV-139, was evaluated as novel biomarker for ovarian cancer. The YDOV-139 cell line was established using ascites samples from a 67-year-old Korean woman with recurrent ovarian cancer, and was characterized with respect to various biological and genetic features. Gene expression profiles were analyzed using cDNA microarrays, and proteomic evaluation was performed by two-dimensional gel electrophoresis (2-DE) and matrix-assisted laser desorption ionization-time of flight peptide mass fingerprinting (MALDI-TOF/PMF). Four candidate markers that were strongly up-regulated in YDOV-139 were validated by real-time polymerase chain reaction (PCR) and immunohistochemistry (IHC). The epithelial-like characteristics of YDOV-139 were evident from morphologic studies, and the average population doubling time was 120 h. When transplanted into nude mice, YDOV-139 cells successfully induced tumor masses in all three animals. Chemosensitivity tests showed that gemcitabine had the highest chemosensitivity index against YDOV-139 cells. HLA typing revealed A*24/A*31, B*07/B*35, Cw03*(09)/w*07, and DRB1*01/ DRB1*15 alleles. Compared with human ovarian surface epithelial (HOSE) cells, 2,520 genes and 23 protein spots were differentially expressed in YDOV-139. Validation by real-time PCR showed that mRNA expression of LCN2, MDK, SLCO4A1, and ER-60 (PDIA3) were strongly elevated in ovarian cancers. In IHC analysis, ER-60 (PDIA3) was significantly overexpressed in both borderline tumors and invasive ovarian cancers (P<0.001). The molecular characteristics of YDOV-139 may have implications for future ovarian cancer research and ER-60 (PDIA3) should be investigated further as a potential biomarker of ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=77954159827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954159827&partnerID=8YFLogxK

U2 - 10.3892/ijo-0000688

DO - 10.3892/ijo-0000688

M3 - Article

VL - 37

SP - 399

EP - 412

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 2

ER -